Studies say a common family toxin increases the risk of death in new corona patients

A common family toxin may increase the risk of complications and death from new crowns, a new study suggests. People exposed to a fungus called asmycin may develop neocovirus-related asmycinosis, which can prove fatal, especially in patients with other diseases, which are a risk factor for COVID-19. Antifellar therapy may improve survival in patients with new coronary-astromycinosis, the researchers said.

Studies say a common family toxin increases the risk of death in new corona patients

Doctors can now save more lives for new crown patients than they did in March and April. New drugs and treatments can prevent fatal complications, although there is still no miracle cure to dramatically reduce deaths. People with multiple underlying diseases are more likely to develop COVID-19 and are at risk of death. Scientists are constantly trying to find drugs that can prevent complications in high-risk patients, and they have observed another important risk factor that can worsen the prognosis of the new crown. It turns out that a toxin that people may come into contact with both indoors and outdoors is associated with severe COVID-19 symptoms.

Researchers from the Johns Hopkins School of Medicine, the National Institutes of Health (NIH) and the Barcelona Hospital Clinic found that asmycin can lead to COVID-19 complications and increase the risk of death. The study is a review of existing research and will be published in the January 2021 issue of the journal Emerging Infectious Diseases, BestLife reported.

Asmycin is a disease caused by exposure to asmycin, a common form of mold that can be found indoors and outdoors. The disease is even more dangerous for patients with COVID-19 who suffer from other diseases. Researchers have added a term for new coronary-mold disease — new coronary pneumonia-related asmycinitis (CAPA). The most common complications in CAPA patients are heart disease, high blood pressure, and geriatrics. These are also risk factors for COVID-19 patients who are not infected with ascertic bacteria.

However, CAPA patients had a “poor efficacy” and higher mortality rate after treatment than other new crown patients. The BestLife report also cites an April study that found that 14 percent of COVID-19 patients had various types of astromycin virus in their respiratory secretions.

These findings may help doctors save more lives. The study, published in the journal Emerging Infectious Diseases, suggests that antifellar therapy may improve survival rates in CAPA patients. Doctors may test new crown patients for asmycin before complications occur.